Dr. Omar H. Butt, MD
Medical Oncology (Medical Oncology Physician)
10 Barnes West Dr, Div Im Medical Oncology, Mob #2
Saint Louis, MO 63141
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 431
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Perelman School of Med at the University of Pennsylvania
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MO license 2020023592 -
Internal Medicine Physician
MO license 2020023592
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 431
- Services billed
- 69,585
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 13,400 | 30 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 11,400 | 13 |
| Injection, nivolumab, 1 mg | 10,800 | 17 |
| Injection, fosaprepitant, 1 mg | 10,500 | 48 |
| Injection, oxaliplatin, 0.5 mg | 7,900 | 18 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 6,060 | 12 |
| Injection, azacitidine, 1 mg | 4,600 | 16 |
| Injection, denosumab, 1 mg | 3,180 | 22 |
| Injection, atropine sulfate, 0.01 mg | 2,300 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,790 | 107 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Saint Louis, MO | 280 |
| Levetiracetam Other prescribers in Saint Louis, MO | 140 |
| Ondansetron Hcl Other prescribers in Saint Louis, MO | 99 |
| Prochlorperazine Maleate Other prescribers in Saint Louis, MO | 66 |
| Lamotrigine Other prescribers in Saint Louis, MO | 60 |
| Gleostine (lomustine) | 57 |
| Pentoxifylline Other prescribers in Saint Louis, MO | 46 |
| Eliquis (apixaban) Other prescribers in Saint Louis, MO | 33 |
| Atorvastatin Calcium Other prescribers in Saint Louis, MO | 30 |
| Lacosamide Other prescribers in Saint Louis, MO | 29 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 16 payments worth $16,873 in total to this clinician.
| Novocure Inc. | $14,848 |
|---|---|
| Menarini Silicon Biosystems, Inc. | $1,808 |
| Exelixis Inc. | $121 |
| Tempus Ai, Inc | $96.43 |
| Honoraria | $13,500 |
|---|---|
| Consulting Fee | $1,680 |
| Food and Beverage | $907 |
| Travel and Lodging | $787 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novocure Inc. Aug 21, 2025 | Honoraria Optune Gio · Oncology | $13,500 |
| Menarini Silicon Biosystems, Inc. Jan 30, 2025 | Consulting Fee Cellsearch · Diagnostics | $1,680 |
| Novocure Inc. Feb 14, 2025 | Travel and Lodging Optune Gio · Oncology · travel to Dallas, TX | $350 |
| Novocure Inc. Mar 8, 2025 | Travel and Lodging Optune Gio · Oncology · travel to Dallas, TX | $247 |
| Novocure Inc. Aug 21, 2025 | Travel and Lodging Optune Gio · Oncology · travel to Dallas, TX | $172 |
| Novocure Inc. Feb 14, 2025 | Travel and Lodging Optune Gio · Oncology · travel to Dallas, TX | $18.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $120,138 in research payments for these studies, mostly to the institutions running them.
- EF-41 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant with Maintenance Temozolomide and…
Novocure GmbH - EF-41/?KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma (EF-41)
Novocure Inc. - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.